Abstract 568: Fibroblast growth factor receptors 2 is a novel therapeutic target in esophagogastric junction adenocarcinoma

In this study, we confirmed that FGFR2 can be a therapeutic target for EGJ adenocarcinoma.Methods: Utilizing 200 cases with EGJ adenocarcinoma (Siewert types I-III), FGFR2 copy number was assayed by Real-time PCR (using RNaseP as a referent), and FGFR2 expression was detected by immunohistochemistry. We examined whether FGFR2 amplification correlates with FGFR2 expression. The associations between FGFR2 expression and clinicopathological factors, and prognostic impact of FGFR2 expression were examined. We investigated the role of FGFR2 in cell proliferation, invasion, apoptosis and cell cycle, using OACM 5.1C (FGFR2 overexpressing cell line), by siRNA technique targeting FGFR2.Results: FGFR2 amplification was detected in 33 (22%) cases, and FGFR2 expression was observed in 112 (58%) cases. FGFR2 amplification significantly correlated with FGFR2 expression (p = 0.045). FGFR2 expression was significantly associated with tumor depth of invasion, nodal involvement, distant metastasis, lymphatic invasion, and vascular invasion (all, p < 0.001). In survival analysis, tumors harboring FGFR2 expression experienced significantly unfavorable outcome (p = 0.039). We observed that si-FGFR2 significantly suppressed phosphorylation of Akt and Erk, resulting in suppressing cell proliferation and invasion; and inducing apoptosis and cell-cycle arrest (p

Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Tokunaga, R., Imamura, Y., Nakamura, K., Ishimoto, T., Iwagami, S., Kurashige, J., Izumi, D., Kosumi, K., Higashi, T., Taki, K., Hiyoshi, Y., Baba, Y., Sakamoto, Y., Miyamoto, Y., Yoshida, N., Hiroshi, S., Oki, E., Maehara, Y., Baba, H. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research